Cancer progression is associated with enhanced directional cell migration, both of the tumour cells invading into the stroma and stromal cells infiltrating the tumour site. In cell-based assays to study directional cell migration, phorbol esters are frequently used as a chemotactic agent. However, the molecular mechanism by which these activators of protein kinase C (PKC) result in the establishment of a polarized migratory phenotype is not known. Here we show that CD44 expression is essential for chemotaxis towards a phorbol ester gradient. In an investigation of CD44 phosphorylation kinetics in resting and stimulated cells, Ser316 was identified as a novel site of phosphorylation following activation of PKC. PKC does not phosphorylate Ser316 directly, but rather mediates the activation of downstream Ser316 kinase(s). In transfection studies, a phosphorylation-deficient Ser316 mutant was shown to act in a dominant-negative fashion to impair chemotaxis mediated by endogenous CD44 in response to a phorbol ester gradient. Importantly, this mutation had no effect on random cell motility or the ability of cells to migrate directionally towards a cocktail of chemoattractants. These studies demonstrate that CD44 functions to provide directional cues to migrating cells without affecting the motility apparatus.
Introduction
The progression of solid tumours from in situ to invasive disease is marked by abnormal cell migration in which the tumour cells acquire the ability to penetrate into the surrounding tissue whereas stromal cells (fibroblasts, leukocytes and endothelial cells) are recruited to the tumour site. Notably, these migration events are not random but stimulated by bidirectional chemotactic signals (Balkwill, 2004; Eccles, 2005) . Consequently chemotaxis, the mechanism by which cells acquire a polarized phenotype in response to a chemoattractant and migrate in a directional manner, has been subject to extensive scrutiny in cancer research. Phorbol esters are able to potently activate protein kinase C (PKC) isoforms by substituting for their natural activator sn-1,2-diacylglycerol (reviewed Liu and Heckman, 1998) . In particular, the tumour-promoting phorbol ester phorbol 12-myristate 13-acetate (PMA), has been used in countless studies to determine the cellular actions of PKC. Treatment of cells with PMA invariably alters cell motility and its activity as a chemotactic agent has been known for over 30 years (Estensen et al., 1973) . However, despite its widespread use in such assays, little is known about the cellular mechanisms involved in responding to a PMA gradient.
CD44 is a widely expressed type I transmembrane glycoprotein that functions as the principal cellular receptor for hyaluronan and as a co-receptor for a number of transmembrane or membrane-linked kinases (Turley et al., 2002; Ponta et al., 2003; Thorne et al., 2004) . Studies from a number of laboratories have focused on how CD44 integrates these adhesive and signalling activities to modulate cell migration, proliferation, differentiation and survival. Given this coordinating role of CD44, it is unsurprising that aberrant CD44 expression has been associated with a number of pathophysiological processes including tumour progression and chronic inflammation (Pure and Cuff, 2001; Martin et al., 2003; Ponta et al., 2003) . In particular, there is increasing in vitro and in vivo evidence for a role for CD44 in tumour cell invasion and metastasis. For example, mice with an APC min mutation or a p53 tm1 mutation are tumour prone and develop distant metastases. When these animals were crossed onto a CD44 null background, there was no change in tumour incidence but a striking reduction in metastasis (Weber et al., 2002) . Two mechanisms have been implicated in the role of CD44 in metastatic disease. First, expression of CD44 by the tumour cells can increase the interaction with endothelial cells and transmigration across an endothelial monolayer (Fujisaki et al., 1999; Mine et al., 2003; Draffin et al., 2004; Ratliff, 2005) . Second, in a wide variety of systems, increased CD44 expression has been shown to correlate strongly with increased invasive potential of tumour cells Jothy, 1999, 2001; Dingemans et al., 2002; Kobayashi et al., 2002; Bourguignon et al., 2003; Xu and Yu, 2003; Kim et al., 2004; Miletti-Gonzalez et al., 2005) and in particular, increasing evidence points to an important role for CD44 in mediating directional cell migration (Alstergren et al., 2004; Avigdor et al., 2004; Zhu et al., 2004 Zhu et al., , 2005 Miletti-Gonzalez et al., 2005; Tzircotis et al., 2005) .
CD44 has been implicated in modulating cellular responses to PMA (Legg et al., 2002; Nagano et al., 2004; Cichy et al., 2005) and phosphorylation events occurring in the cytoplasmic tail of CD44 have been shown to modulate the chemotactic response towards PMA (Legg et al., 2002) . In resting cells, CD44 is constitutively phosphorylated to high stoichiometry (up to 40%) on a single serine residue, Ser325 (Neame and Isacke, 1992; Pure et al., 1995; Peck and Isacke, 1998) . A more complicated picture has emerged with respect to the phosphorylation status of CD44 in phorbol esterstimulated cells. Initially, it was demonstrated that CD44 can be phosphorylated in vitro by PKC (Kalomiris and Bourguignon, 1989) but 32 P-orthophosphate labelling of PMA-treated cells revealed no change in overall CD44 phosphorylation levels (Camp et al., 1991; Neame and Isacke, 1992) . These contradictory observations were resolved when it was demonstrated that PMA treatment results in a complete de-phosphorylation of CD44 at Ser325 and concomitant phosphorylation at one or more other serine residues (Legg et al., 2002) . Ser291, which lies in a consensus PKC phosphorylation sequence, was the only CD44 cytoplasmic tail serine shown to be phosphorylated by PKC in vitro (Lewis et al., 2001; Legg et al., 2002) . However, these studies did not investigate whether Ser291 is the sole site of CD44 phosphorylation in vivo. The work described here establishes a direct involvement of CD44 in cell chemotaxis towards a phorbol ester gradient and uncovers a role for a novel CD44 phosphorylation event in this process.
Results
Chemotaxis towards a phorbol ester gradient is CD44-dependent To directly investigate a role for CD44 in mediating directional cell migration towards a phorbol ester gradient, CD44 expression was downregulated in NIH-3T3 cells by short interfering RNA (siRNA) treatment ( Figure 1a ) and cell chemotaxis monitored using a Dunn chemotaxis chamber assay (Figure 1b) . The advantage of this direct viewing system over the more commonly used Boyden chamber is that cells are tracked and analysed individually, allowing the directional response to be determined independently of migration speed (Zicha et al., 1991) . Untreated parental NIH-3T3 cells, mock-transfected cells (data not shown) and cells transfected with control siRNA oligonucleotides showed statistically significant chemotaxis up a PMA gradient. By contrast, cells treated with CD44 siRNA oligonucleotides were unable to respond to the gradient. Importantly, there was no difference in the migration speed of cells treated with CD44 or control siRNA oligonucleotides, demonstrating that CD44 is required for directional sensing of a PMA gradient but not cellular locomotion.
CD44 is phosphorylated at Ser316 following both phorbol ester and dibutyryl cAMP treatment Of the seven cytoplasmic serine residues in human CD44, five are conserved between species (Ser291, Ser316, Ser323, Ser325, Ser337) (Thorne et al., 2004) (Figure 2a ). In PKC in vitro kinase assays, the only cytoplasmic residue to be phosphorylated is Ser291 ( Parental NIH-3T3 cells were seeded onto laminincoated coverslips, serum-starved overnight in 0.25% DCS and then transfected with either control siRNA oligonucleotides or murine CD44 siRNA oligonucleotides. Sixty-four hour later, cell migration towards 100 nM PMA was assayed using Dunn chemotaxis chambers. The data are presented as a circular histogram in which each 181 segment represents the total number of cells with an average angle of migration falling within that particular interval. The Rayleigh test for unimodal clustering is used to verify directional migration. If cells show statistically significant directional migration, the mean migration angle is displayed as an arrow and the 95% confidence interval as a grey sector. The number of cells analysed (n) and the average speed of migration for each treatment is given. The data presented were pooled from two independent experiments. CD44-dependent chemotaxis towards phorbol esters G Tzircotis et al the CD44 cytoplasmic domain failed to reveal any additional PKC consensus phosphorylation sites. However, it was noted that Ser316 lies in a classic cAMPdependent protein kinase (PKA) consensus site defined as Arg/Lys-Arg/Lys-X (any amino acid)-Ser/Thr (Pure et al., 1995) . To determine whether PKA could phosphorylate Ser316, synthetic peptides incorporating either a phosphorylated or unmodified serine in the 316 position ( Figure 2a ) were subject to PKA in vitro kinase assays. PKA showed essentially no phosphorylation of the phosphorylated Ser316 peptide but readily phosphorylated the unmodified peptide.
32
P incorporation into the latter was B30% that observed with the universal Kemptide reagent indicating that PKA can phosphorylate Ser316 directly (Figure 2b ).
To investigate whether Ser316 was also subject to phosphorylation in vivo, CD44 phosphorylation was examined in unstimulated and stimulated cells. CD44
immunoprecipitates were probed with a commercial phospho-PKA substrate antibody (raised against degenerate phosphopeptides corresponding to the PKA consensus sequence) that would be predicted to reflect phosphorylation at Ser316 (Figure 2c ). In keeping with previous reports that CD44 is not phosphorylated at Ser316 in resting cells (Neame and Isacke, 1992; Pure et al., 1995; Peck and Isacke, 1996) , CD44 immunoprecipitated from untreated cells showed no reactivity towards the phospho-PKA substrate antibody. However, reactivity was detected against CD44 immunoprecipitated from either Flow2000 human fibroblasts or MDA-MD-468 breast carcinoma cells following PKA activation by treatment with the cell-permeable cAMP analogue dibutyryl (Bt 2 ) cAMP. Surprisingly, reactivity towards the PKA substrate antibody was also observed in CD44 immunoprecipitated from PMA-treated cells.
To monitor phosphorylation at Ser325 following kinase CD44-dependent chemotaxis towards phorbol esters G Tzircotis et al activation, CD44 immunoprecipitates were probed in parallel with the CD44 phosphoSer325-specific monoclonal antibody (mAb), 18E2. As previously reported (Legg et al., 2002) , phorbol ester treatment resulted in de-phosphorylation at Ser325. In contrast, the level of Ser325 phosphorylation remained unchanged in Bt 2 cAMP-treated cells.
These results suggest that Ser316 is phosphorylated following cellular activation of either PKA or PKC. However, given the consensus sequences recognized by both PKA and PKC are structurally related (Pearson and Kemp, 1991) , the possibility remained that the reactivity observed with the PKA substrate antibody resulted from cross-recognition of another phosphorylated serine residue. To address this, a polyclonal antibody was raised against a synthetic CD44 cytoplasmic domain peptide containing a phosphorylated serine at position 316 ( Figure 2a ; see Materials and methods). The resulting antibody reacted strongly with CD44 immunoprecipitated from Bt 2 cAMP-treated cells and moreover, antibody reactivity could be blocked by incubation with the immunizing phosphorylated peptide but not by the equivalent non-phosphorylated peptide or by a control serine phosphopeptide (Figure 3a) . To further confirm the specificity of the anti-phosphoSer316 antibody, NIH-3T3 cells were transfected with wild-type human CD44 (WT CD44) or CD44 in which Ser291, Ser316 and Ser325 had been changed to alanine, CD44 S291A, CD44 S316A and CD44 S325A, respectively. Populations of transfected cells were selected for equivalent human CD44 expression levels by FACS sorting with mAb E1/2 that recognizes an extracellular antiphosphoSer325 NIH-3T3 cells transfected with vector alone, WT CD44, CD44 S291A, CD44 S316A or CD44 S325A were selected in G418 and populations of transfectants expressing equal amounts of CD44 were isolated by FACS sorting. Panel b shows flow cytometric analysis of expression levels using Alexa488-conjugated mAb E1/2 demonstrates expression levels. In panel c, transfected cells were cultured overnight and then left untreated or treated for 1 h at 371C with 100 nM PMA or 1 mM Bt 2 cAMP and CD44 immunoprecipitated with the anti-human CD44 mAb E1/2. Immunoprecipitates were Western blotted with anti-phosphoSer316 CD44 antibody, anti-phosphoSer325 CD44 mAb 18E2 or anti-CD44 antibody CT-1. Molecular weight markers are in kilo Daltons.
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G Tzircotis et al domain epitope on human but not mouse CD44 ( Figure 3b ). As shown in Figure 3c , the anti-phosphoSer316 antibody reacted with WT CD44 immunoprecipitated from either PMA or Bt 2 cAMP-treated cells and this reactivity was lost in the S316A mutant but not in either the S291A or S325A mutants. As expected, the phosphoSer325 CD44 mAb 18E2 did not react with the CD44 S325A mutant and in agreement with the data obtained with endogenous CD44 (Figure 2b ), Ser325 phosphorylation of transfected CD44 decreased following PMA but not Bt 2 cAMP treatment. In these experiments, a low level of Ser316 phosphorylation was detected in unstimulated cells but with a notable increase following treatment with PMA and Bt 2 cAMP. As the cell lines used in this analysis have been selected for high levels of transfected human CD44 expression, this most likely reflects a low level activation of CD44. Finally, to ensure that reactivity of the anti-phosphoSer316 antibody was not dependent on expression of exogenous CD44, the phosphorylation status of endogenous CD44 from MDA-MB-468 cells was examined. Identical results were obtained in that the antiphosphoSer316 antibody reacted with CD44 immunoprecipitated from either PMA or Bt 2 cAMP-treated cells but not from untreated cells (see Figure 4 ). These data demonstrate that Ser316 is a bona fide site of CD44 phosphorylation in vivo.
Phorbol ester mediated phosphorylation of CD44 at Ser316 arises through independent signalling pathways following activation of PKC and PKA An unexpected result from these studies was that Ser316 is phosphorylated both following stimulation of cells with PMA to activate PKC and with Bt 2 cAMP to activate PKA. However, although PKA can phosphorylate Ser316 in vitro (Figure 2b ), no Ser316 phosphorylation is observed in a PKC in vitro kinase assay (Legg et al., 2002) . To better delineate the mechanism of Ser316 phosphorylation, both time-course and inhibitor experiments were undertaken. Ser316 phosphorylation following either PMA or Bt 2 cAMP treatment commenced after 5 min and reached a maximum level at 30 min (Figure 4 ). PMA treatment resulted in the dephosphorylation of CD44 at Ser325, which again was visible within 5 min and reached a maximum at 30 min. Consistent with the previous experiments, Bt 2 cAMP treatment did not alter Ser325 phosphorylation levels. The relatively slow kinetics of these phosphorylation and de-phosphorylation events suggest that a ratelimiting step may be the recruitment of kinases and/or phosphatases to the CD44 cytoplasmic domain. However, the identical kinetics observed with the PKC and PKA activators shown here ( Figure 4 ) and with shorter stimulation times (1-11 min, data not shown) meant that no conclusions could be drawn as to a potential kinase activation sequence. To address this, MDA-MB-468 cells were pretreated with the PKC inhibitor Bisindolylmaleimide I (Bis I) (Toullec et al., 1991) , the PKA inhibitor H-89 (Chijiwa et al., 1990) or carrier followed by stimulation with PMA or Bt 2 cAMP or no further treatment (Figure 5a ). Figure 4 Kinetics of Ser316 phosphorylation following PMA and Bt 2 cAMP stimulation. MDA-MB-468 cells were treated for 0-60 min at 371C with either 100 nM PMA or 1 mM Bt 2 cAMP and CD44 phosphorylation status assayed as described in Figure 3c . The data shown are representative of three independent experiments.
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antiphosphoSer325 followed by stimulation for 1 h at 371C with 100 nM PMA, 1 mM Bt 2 cAMP or no further treatment. In both panels, the phosphorylation status of CD44 was assayed as described in Figure 3c . One explanation for these results is that phosphorylation of CD44 at Ser316 following PMA treatment results from a sequential process in which activation of PKC results in activation of PKA whereas de-phosphorylation of Ser325 is independent of PKA activation. However, a limitation of this interpretation concerns the absolute specificity of kinase inhibitors employed, and in particular the specificity of H-89. H-89 is a cyclicnucleotide-based analogue that interacts with the ATPbinding pocket of PKA but has also been demonstrated to inhibit other kinases (Davies et al., 2000) . We therefore repeated the assay with the chemically distinct PKA inhibitor 14-22, a myristoylated peptide corresponding to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase (Glass et al., 1989) . As shown in Figure 5b , pretreatment of cells with 14-22 completely prevented phosphorylation of Ser316 when the cells were stimulated with Bt 2 cAMP whereas there was no effect on Ser316 phosphorylation following PMA stimulation. Taken together, these data provide strong evidence that PKA does not act downstream of PKC and that the pathways mediating the PKA-and PKC-dependent phosphorylation of Ser316 are independent. Moreover, as Ser316 can be directly phosphorylated by PKA in vitro (Figure 2 ) and can be effectively blocked by different PKA inhibitors in situ this suggests that Ser316 is a likely in vivo substrate for PKA. In contrast, the partial inhibition of Ser316 phosphorylation obtained with the H-89 compound following PMA stimulation is most likely due to effects on kinase(s) other than PKA.
To address what signalling pathway(s) are involved in CD44 phosphorylation events following activation by phorbol ester, we reconsidered the results in Figure 5a . Although Bis I and H-89 are commonly used as specific antagonists of PKC and PKA, respectively, analysis of their in vitro inhibition profile reveals overlapping inhibition of other kinases including MAPKAP-K1b (p90 RSK ), MSK1 and S6K1 (Davies et al., 2000) . MAPKAP-K1b is directly activated by the MAP kinases ERK1/2 (Zhao et al., 1996) and MSK1 is activated by ERK2 (Deak et al., 1998) . Consequently, the involvement of the ERK signalling cascade in CD44 phosphorylation was investigated by repeating the assay in the presence of inhibitors of MEK1/2 kinases that are directly upstream of ERK1/2 (Favata et al., 1998) . Accordingly, MDA-MB-468 cells were preincubated with either UO126 or PD 98059 before stimulation with PMA or 8-bromoadenosine 3 0 :5 0 -cyclic monophosphate (8-Br-cAMP) (Figure 6) . These data first demonstrate that the CD44 phosphorylation status in response to a different membrane-permeable non-cleaved cAMP analogue CD44, 8-Br-cAMP, is identical to that observed with Bt 2 cAMP ( Figure 5) . Second, they demonstrate that CD44 Ser316 phosphorylation following PMA or 8-BrcAMP is not altered by treatment with the MEK inhibitors. Similarly, the inhibitors do not affect the phosphorylation state of Ser325 in the control or 8-BrcAMP-treated cells nor the de-phosphorylation response at Ser325 after PMA stimulation. Western blotting with anti-phosphoERK antibodies confirmed that both UO126 and PD 98059 effectively inhibited ERK phosphorylation although interestingly, 8-Br-cAMP treatment alone suppressed ERK phosphorylation below controls levels without affecting ERK expression.
Ser316 phosphorylation is critical for cell chemotaxis up a phorbol ester gradient
To determine whether Ser316 phosphorylation is required for CD44-mediated chemotaxis, NIH-3T3 cells expressing human WT CD44 or CD44 phosphorylation mutants ( Figure 3b ) were subjected to Dunn chemotaxis chamber assays (Figure 7) . Unsurprisingly, NIH-3T3 cells expressing WT human CD44 migrated directionally up a phorbol ester gradient. Expression of a human CD44 S325 mutant, which cannot be constitutively phosphorylated in resting cells (Peck and Isacke, 1998) , does not interfere with the ability of NIH-3T3 cells to sense the PMA gradient. It has previously been shown that mutation of Ser291 results in an impaired CD44-ezrin interaction and a block in cell chemotaxis towards PMA (Legg et al., 2002) . In agreement, we show here that NIH-3T3 cells expressing the CD44 S291A mutant have impaired chemotaxis towards PMA. In this paper, we have identified Ser316 as a novel CD44 phosphor- Figure 6 Inhibition of the ERK signalling pathway does not influence phosphorylation of CD44 at Ser316. MDA-MB-468 cells were treated for 30 min at 371C with 10 mM of the MEK inhibitors UO126 or PD 98059 or carrier (0.1% DMSO) followed by stimulation for 1 h at 371C with 100 nM PMA, 1 mM 8-Br-cAMP or no further treatment. Western blots were performed on CD44 immunoprecipitates as described in Figure 3c . Cell lysates were probed for phosphoERK before stripping the membrane and reprobing for total ERK. The immunoblot is representative of three independent experiments. CD44-dependent chemotaxis towards phorbol esters G Tzircotis et al ylation site following PMA stimulation and show that cells expressing the CD44 S316A mutant are unable to migrate directionally in a phorbol ester gradient. For both the S291A and S316A mutants, this defect in chemotaxis is not due to a general impairment in cell migration as no significant difference in migration speed is observed in any of the transfected populations. Similarly, there is no general impairment in the chemotactic machinery as cells expressing WT CD44, CD44 S291A and CD44 S316A all display significant chemotaxis in a gradient of DCS that contains a cocktail of chemotactic factors. Importantly, as parental NIH-3T3 cells display CD44-dependent chemotaxis towards PMA (Figure 1) , it can be concluded that both the S291A and S316A mutants function in a dominantnegative fashion to override the CD44-dependent PMA gradient sensing machinery of the cells.
Discussion
In this study, we have demonstrated an essential role for CD44 in cell chemotaxis towards a phorbol ester gradient and the requirement in this process for phosphorylation at a novel site in the CD44 cytoplasmic domain. It had previously been established that CD44 in resting cells is solely phosphorylated at Ser325 (Peck and Isacke, 1998; Lewis et al., 2001) and that stimulation results in complete de-phosphorylation of this residue but maintenance of the overall phosphorylation level of CD44 (Camp et al., 1991; Neame and Isacke, 1992; Legg et al., 2002) . Studies into the mechanism of this phosphorylation switch identified Ser291 as the only residue subject to direct phosphorylation by PKC in vitro but the role of other residues in vivo had not been investigated. Here, we have conclusively demonstrated that Ser316 is phosphorylated in response to cell stimulation. By generating a phosphoSer316-specific antibody, it was found that Ser316 phosphorylation of endogenous and transfected CD44 occurs in response to PKA or PKC activation in all primary cells and established cell lines examined (Figures 2, 3 and 5) including primary human monocyte-derived macrophages (data not shown). Moreover, in vitro kinase and inhibitor assays revealed that phosphorylation of Ser316 is mediated by either cellular activation of PKA Phosphorylation of CD44 at Ser316 is critical for directional migration towards PMA. NIH-3T3 cells expressing WT CD44, CD44 S291A, CD44 S316A and CD44 S325A were seeded onto laminin-coated coverslips, serum-starved overnight in 0.25% DCS and 72 h later, cell migration towards 100 nM PMA or 10% DCS was assayed using the Dunn chemotaxis chambers as described in Figure 1 . The number of cells analysed (n) and the average speed of migration for each treatment is given. The data presented were pooled from four independent experiments.
CD44-dependent chemotaxis towards phorbol esters G Tzircotis et al or PKC but this phosphorylation arises through independent signalling pathways. In particular, PKA can phosphorylate Ser316 directly whereas the effects of PMA are particularly complex as this pathway not only invokes the indirect phosphorylation of Ser316 but also concomitant dephosphorylation of Ser325. The identities of the Ser316 kinase and Ser325 phosphatase acting downstream of PKC have yet to be identified but these studies have ruled out PKA and mitogen-activated protein kinases in this process. In addition to the phorbol ester-binding PKC isoenzymes, PMA has been reported to bind other receptors such as the chimaerins (Caloca et al., 1999) , Ras guanyl-releasing protein (ElShemerly et al., 1997; Ebinu et al., 1998) and protein kinase Ds (Van Lint et al., 2002) . Importantly, this study and previous studies (Legg et al., 2002) have demonstrated that the effects of PMA treatment on CD44 Ser316 phosphorylation and Ser325 dephosphorylation are mediated via activation of PKC as the PKC inhibitors Ro-31 and Bis-I are effective in blocking these phosphorylation/dephosphorylation events. What is notable in these studies is that these phosphorylation events occur relatively slowly, suggesting a requirement for targeted localization of kinases and/or phosphatases. For both PKC and PKA, localization is regulated by binding proteins known as receptors for activated C-kinases and A-kinase anchoring proteins (AKAPs), respectively. The AKAPs are a family of proteins comprising more than 30 members only related to each other by their ability to bind to the PKA regulatory subunit. In the cell, approximately 75% of PKA is associated with AKAPs (Sim and Scott, 1999) . A candidate AKAP in the phosphorylation of CD44 is ezrin (Dransfield et al., 1997) , a member of the ERM family of proteins that interact with CD44 at a membrane proximal site in the CD44 cytoplasmic tail (Legg and Isacke, 1998; Yonemura et al., 1998) . Alternatively, the four terminal amino acids (Lys-IleGly-Val) correspond to a consensus postsynaptic density protein/discs-large protein/zonula occludens-1 (PDZ) domain binding motif (Thorne et al., 2004) . PDZ domain containing proteins commonly form complexes with kinases, raising the interesting possibility that the mechanism of CD44 phosphorylation involves PKA and/or PKC recruitment via PDZ interactions.
The second key finding of the data presented here is that the CD44 S291A and S316A phosphorylation mutants can act in a dominant-negative fashion to suppress the chemotactic response of parental cells to a gradient of PMA. Although a number of intracellular signalling pathways involved in the polarization and directional migration of cells have been characterized (Jones, 2000; Weiner, 2002; Van Haastert and Devreotes, 2004) , relatively little is known as to how these signal transduction components are coupled to the transmembrane receptors that sense the chemotactic gradient. Previously, we have demonstrated that the CD44 S291A mutant blocks the chemotactic migration of CD44-expressing MDA-MB-435 breast cancer cells up a PMA gradient. The mechanism of this dominantnegative activity is that the CD44 S291A mutant binds ezrin in unstimulated cells but cannot release ezrin following PMA treatment (Legg et al., 2002) . Given that the CD44 S316A mutant also has dominant-negative activity it may be that this mutant similarly sequesters signalling components away from endogenous receptors. Alternatively, as exogenous mutant receptors are expressed at a higher level than endogenous receptors, CD44 S291A and S316A mutants may disrupt downstream signalling events by displacing endogenous CD44 from plasma membrane microdomains. One demonstrated function of such domains is to organize the gradient-sensing machinery to the leading edge of migrating cells (Gomez-Mouton et al., 2004) . It is certainly of interest that in migratory cells, including NIH-3T3 cells, a proportion of CD44 is partitioned into detergent-insoluble glycolipid enriched microdomains whereas in non-migratory cells, all of the CD44 population can be extracted into a detergent-soluble fraction (Neame et al., 1995; Perschl et al., 1995) . Finally, the finding that effects of the S291A and S316A mutants are restricted to the directional response and have no effect on cell motility per se, show that the function of CD44 appears to involve sensing of the chemotactic gradient.
In conclusion, CD44 undergoes complex changes in phosphorylation between resting and stimulated states. Two key serine residues, Ser291 and Ser316, have been identified as regulating CD44-dependent chemotaxis. The demonstration that mutation of these sites has no effect on cell motility indicates that the primary function of CD44 in this system is in sensing specific chemotactic signals. The priority in future studies will be to identify physiological mediators of PKC activation, which regulate CD44 phosphorylation and cell chemotaxis and to establish whether blocking the interaction of cytoplasmic components with phosphorylated CD44 can impair cell chemotaxis in tumour progression models.
Materials and methods
Cell lines and constructs MDA-MB-468 (ATCC) and Flow2000 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal bovine serum. NIH-3T3 cells were obtained from Professor C Marshall (Institute of Cancer Research) and were cultured in DMEM plus 10% donor calf serum (DCS). pSRa vector containing the standard form of human CD44 (pSRa-CD44, (Neame and Isacke, 1993) ) or CD44 containing alanine substitutions at Ser291 (pSRa-CD44 S291A), Ser316 (pSRa-CD44 S316A), Ser325 (pSRa-CD44 S325A) have been previously described (Neame and Isacke, 1992; Legg et al., 2002) . Cells were transfected using the Lipofectamine reagent (Invitrogen, Paisley, UK) and selected in 0.6 mg/ml G418 (Invitrogen). Populations of cells expressing equivalent levels of human CD44 were selected by FACS sorting. For siRNA transfection, NIH-3T3 fibroblasts were transfected with a SMARTpool s combination of 4 siRNA oligonucleotides against murine CD44 (Dharmacon, Chicago, IL, USA) or control siRNA oligonucleotides using Oligofectamine (Invitrogen) in Opti-MEM reduced serum medium (Invitrogen). Cells were incubated at 371C for 4 h before the addition of Peptides and antibodies All peptides were above 80% purity as determined by analytical ion-spray mass spectrometry and reverse-phase high-performance liquid chromatography. The CD44 phosphoSer316 antibody was generated by AMS Biotech (Abingdon, UK). Briefly, a New Zealand white rabbit was immunized with peptide EDRKPSpGLNGE (Sp denotes a phosphorylated serine residue), which corresponds to the CD44 sequence Glu311-Glu321 (Figure 2a ) conjugated to keyhole limpet haemocyanin (KLH). Sera were affinity purified by passing first through a column containing the equivalent non-phosphorylated peptide (EDRKPSGLNGE) conjugated to agarose. The flow through was then passed over a EDRKPSpGLNGE-agarose column and bound antibody eluted in 100 mM Glycine buffer, pH 2.5, neutralized by addition of 2 M Tris.HCl, pH 8.0, dialysed in PBS and finally diluted 1:1 in 300 mM NaCl, 2% BSA, 0.18% NaN 3 , 60% glycerol in PBS before storage at À761C. Peptide LNGEASKSpQEMVH (Chiron Technologies Pty Ltd, Sydney, Australia), which corresponds to the CD44 sequence Leu318-His330, was used as a control. CT-1 is a polyclonal antibody against the CD44 cytoplasmic domain that was generated by immunization of a New Zealand white rabbit with a bacterially expressed GST-human CD44 cytoplasmic domain construct. mAb E1/2.8 specific for human CD44, mAb IM7.8.1 which recognizes human and mouse CD44 and mAb 18E2 which specifically recognizes CD44 phosphorylated at Ser325 have been described previously (Trowbridge et al., 1982; Isacke et al., 1986; Lewis et al., 2001) . mAb E1/2 was directly conjugated to Alexa Fluor s 488 using a Molecular Probes (Paisley, UK) microscale protein labelling kit (Invitrogen). Anti-PKA substrate antibody was purchased from Cell Signalling Technology (Beverley, MA, USA). Polyclonal antibodies to ERK, the anti-phosphoERK monoclonal antibody (directed against dually phosphorylated ERK1 and ERK2 isoforms) and the anti-a-tubulin antibody were purchased from Sigma. HRP-conjugated second layer antibodies were purchased from Jackson ImmunoResearch (West Grove, PA, USA).
PKA in vitro kinase assay Small-scale 20 ml PKA phosphorylation reactions were carried out at 301C for 30 min in buffer containing 50 mM Tris-HCl, pH 7.5. and 10 mM MgCl 2 . Each reaction contained 130 mM of either Kemptide, phosphoSer316 or non-phosphoSer316 peptide and was initiated by addition of 10 mCi [g-32 P]ATP. Reactions were terminated by addition of protein kinase A inhibitor peptide 14-22 to a final concentration of 500 nM and 10 ml spotted onto Whatman P81 phosphocellulose filters. The filters were then washed three times for 5 min in 1% phosphoric acid, once for 5 min in ethanol and dried before Cherenkov counting.
Chemotaxis assays
Chemotaxis was measured by direct observation and recording of cell behaviour in stable concentration gradients using Dunn chemotaxis chambers (Hawksley Technology, Lancing, UK) as described previously (Zicha et al., 1991; Allen et al., 1998; Tzircotis et al., 2005) . Briefly, glass coverslips were coated with 1 mg/ml laminin (BD Biosciences, Cowley, UK) in PBS for 1 h at room temperature, washed twice with DMEM and then seeded with 5 Â 10 4 cells per coverslip. Following overnight incubation, cells were cultured in DMEM with 0.25% DCS for 12 h before setting up the chemotaxis chambers. The Dunn chemotaxis chamber is a glass slide into which two concentric rings are cut. Inverting a coverslip over these forms two chambers separated by a bridge. Filling the outer chamber with chemoattractant results in a stable concentration gradient spanning the bridge between the two chambers and cell migration in this area is then observed. In these experiments, DMEM/0.25% DCS was placed in the inner chamber and DMEM/0.25% DCS supplemented with 100 nM PMA in the outer chamber. Fields were selected and filmed with a time-lapse interval of 10 min for 8 h. The Rayleigh test for unimodal clustering of directions was used to determine whether there was a significant chemotactic response. Note that this analysis only provides a measurement of statistical significance and not a measurement of the strength of the chemotactic response. A uniform distribution (random cell motility) of the data was assumed if the P-value for the calculation was greater than 0.05.
